These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 27017616

  • 1. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S, Jansen M, Matsushima N, Chen S, Mendell J.
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M, Horiike A, Murakami H, Yamamoto N, Kaneda H, Nakagawa K, Horinouchi H, Nagashima M, Sekiguchi M, Tamura T.
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [Abstract] [Full Text] [Related]

  • 3. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Shimizu T, Yonesaka K, Hayashi H, Iwasa T, Haratani K, Yamada H, Ohwada S, Kamiyama E, Nakagawa K.
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):489-495. PubMed ID: 28144730
    [Abstract] [Full Text] [Related]

  • 4. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
    Mendell J, Freeman DJ, Feng W, Hettmann T, Schneider M, Blum S, Ruhe J, Bange J, Nakamaru K, Chen S, Tsuchihashi Z, von Pawel J, Copigneaux C, Beckman RA.
    EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
    [Abstract] [Full Text] [Related]

  • 5. The prospect of patritumab for treating non-small cell lung cancer.
    Horinouchi H.
    Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
    Schmid U, Liesenfeld KH, Fleury A, Dallinger C, Freiwald M.
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
    [Abstract] [Full Text] [Related]

  • 9. Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors.
    Lu Y, Shimizu S, Sawamura R, Tajima N, He L, Lee M, Abutarif M, Shi R.
    J Clin Pharmacol; 2023 Jan; 63(1):77-90. PubMed ID: 36053771
    [Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R, Roskos LK, Robbie GJ.
    Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
    [Abstract] [Full Text] [Related]

  • 11. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso, Guidi M, Khoudour N, Pascaline Boudou-Rouquette, Fabre E, Tlemsani C, Arrondeau J, François Goldwasser, Vidal M, Schneider MP, Wagner AD, Widmer N, Blanchet B, Csajka C.
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
    Thai HT, Veyrat-Follet C, Mentré F, Comets E.
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
    [Abstract] [Full Text] [Related]

  • 13. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.
    Chen R, Li J, Hu WW, Wang ML, Zou SL, Miao LY.
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1111-23. PubMed ID: 24061864
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
    Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P.
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146
    [Abstract] [Full Text] [Related]

  • 15. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
    Gupta N, Zhao Y, Hui AM, Esseltine DL, Venkatakrishnan K.
    Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318
    [Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
    Alifrangis L, Schoemaker R, Skartved NJ, Hald R, Montagut C, Kopetz S, Tabernero J, Kragh M, Wade JR.
    J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):5-18. PubMed ID: 31679083
    [Abstract] [Full Text] [Related]

  • 17. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.
    Wakui H, Yamamoto N, Nakamichi S, Tamura Y, Nokihara H, Yamada Y, Tamura T.
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):511-6. PubMed ID: 24442032
    [Abstract] [Full Text] [Related]

  • 18. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
    Mo G, Baldwin JR, Luffer-Atlas D, Ilaria RL, Conti I, Heathman M, Cronier DM.
    Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM.
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
    Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S.
    J Clin Pharmacol; 2013 Nov; 53(11):1103-11. PubMed ID: 23922054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.